2024
Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis
Islam A, Díaz L, Idalsoaga F, Guizzetti L, Mortuza R, Dunn W, Singal A, Simonetto D, Ramirez-Cadiz C, Zhang W, Qian S, Cabezas J, Sarin S, Maiwall R, Jalal P, La Tijera F, Skladany L, Bystrianska N, Rincon D, Chacko K, Cots M, Garcia-Tsao G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis. Hepatology Communications 2024, 8: e0573. PMID: 39445912, PMCID: PMC11512629, DOI: 10.1097/hc9.0000000000000573.Peer-Reviewed Original ResearchViral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.
Hsu C, Wang L, Maestri E, Jacob A, Do W, Mayo S, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang X, Schnabl B. Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. Hepatology 2024 PMID: 39325984, DOI: 10.1097/hep.0000000000001046.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderHigher Child-Pugh scoreSerological profileAntibody responseAssociated with very high mortalityUse disorderDecompensation of liver diseaseChild-Pugh scoreActive alcohol useNinety-day mortalityAssociated with decompensationMulticenter observational studyViral antibody responseMonths of diagnosisAntibody repertoireSera of patientsMultiorgan dysfunctionPoor prognosisNinety-daySerological biomarkersHealthy controlsPatient seraLiver diseaseAntibody targetingRelationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Al-Karaghouli M, Ventura-Cots M, Wong Y, Genesca J, Bosques F, Brown R, Mathurin P, Louvet A, Shawcross D, Vargas V, Verna E, Schnabl B, Caballeria J, Shah V, Kamath P, Lucey M, Garcia-Tsao G, Bataller R, Abraldes J. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. Hepatology Communications 2024, 8: e0495. PMID: 39082963, DOI: 10.1097/hc9.0000000000000495.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisTrial designRandomized controlled trialsShort-term mortalityInclusion criteriaPredictive valuePrognostic valueControlled trialsShort-term benefitsEfficient trial designTrial outcomesAssociated with significant mortalityCourse of AHCohort of patientsTreatment decisionsSample sizeOrdinal outcomesMortalityOrdinal scaleMELD valuesLandmark analysisTransplant allocationTrialsOutcomesTransplantationFaecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis
Kreimeyer H, Gonzalez C, Fondevila M, Hsu C, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez D, Schnabl B. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut 2024, gutjnl-2024-332730. PMID: 39033024, DOI: 10.1136/gutjnl-2024-332730.Peer-Reviewed Original ResearchAlcohol-associated hepatitisShort-term survivalMulticentre cohortSeverity of ALDAlcohol-associated liver diseaseIndependent validation cohortInduce gut dysbiosisNon-invasive markerAlcohol-use disordersNeutrophil degranulationPrediction of short-term survivalPrognostic effectHepatic neutrophilsValidation cohortBacterial translocationNeutrophil granulesMPO levelsLiver diseaseFecal biomarkersTandem mass tagPatientsGut dysbiosisLiver damageDisease severityNeutrophilsAn artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn W, Li Y, Singal A, Simonetto D, Díaz L, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology 2024, 80: 1196-1211. PMID: 38607809, DOI: 10.1097/hep.0000000000000883.Peer-Reviewed Original ResearchAlcohol-associated hepatitisValidation cohortArtificial intelligenceModified Glasgow scoreMaddrey's discriminant functionMortality rateGlobal cohort studyShort-term mortalityPost-test probabilityApproximate mortality ratesSteroid therapyGlasgow scoreAH patientsSteroid useTransplant indicationRetrospective studyDerivation cohortLaboratory valuesCohort studyClinical trialsGlobal cohortPrognostic modelScoring systemAI algorithmsCohortSerum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis
Yamazaki T, Kouno T, Hsu C, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Schnabl B. Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. Hepatology 2024, 80: 403-417. PMID: 38377466, PMCID: PMC11268475, DOI: 10.1097/hep.0000000000000777.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderSevere AHAH patientsAhR activationMicrobiota-derived tryptophan metabolitesSurvival rateAssociated with high mortalityCumulative survival rateAssociated with survivalAryl hydrocarbon receptor activationMulticenter cohortFecal metabolomePrognostic markerTryptophan metabolitesReceptor activationAryl hydrocarbon receptorPatientsUse disorderAH cohortSerumHigher mortalityAhRHepatitisCohortP-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY
Idalsoaga F, Díaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY. Annals Of Hepatology 2024, 29: 101206. DOI: 10.1016/j.aohep.2023.101206.Peer-Reviewed Original ResearchRenal replacement therapyVariables associated with mortalityModerate AHAlcohol-associated hepatitisPrognostic factorsLiver transplantationMaddrey's discriminant functionAssociated with high mortalityMultiple organ failureRetrospective cohort studyMultivariate-adjusted modelsShort-term mortalityAssociated with mortalityCompeting-risks modelMedian ageCause of deathReplacement therapyMulticenter studyMELD scoreOrgan failureUnivariate analysisCohort studyFrequent causeSevere entitySurvival rateP- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY
Idalsoaga F, Diaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Agrawal B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY. Annals Of Hepatology 2024, 29: 101227. DOI: 10.1016/j.aohep.2023.101227.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injurySevere AHPentoxifylline useLiver transplantationKidney injuryMaddrey's discriminant functionAssociated with increased mortalityHistory of cirrhosisSubgroup of patientsRetrospective cohort studyMultivariate-adjusted modelsEffect of pentoxifyllineAssociated with mortalityCompeting-risks modelMedian ageSerum creatinineMELD scoreUnivariate analysisCohort studyFemale sexPentoxifyllineDecreased survivalSevere entityPatients
2023
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
Díaz L, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Valverde M, Perez D, Gómez J, Escarate R, Villalón A, Ramírez C, Hernandez-Tejero M, Zhang W, Qian S, Simonetto D, Ahn J, Buryska S, Dunn W, Mehta H, Agrawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Abdulsada S, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Salazar P, Skladaný L, Bystrianska N, Clemente-Sanchez A, Villaseca-Gómez C, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Castro-Sanchez S, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Louvet A, García-Tsao G, Roblero J, Abraldes J, Shah V, Kamath P, Arrese M, Singal A, Bataller R, Arab J. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Reports 2023, 5: 100727. PMID: 37456675, PMCID: PMC10339256, DOI: 10.1016/j.jhepr.2023.100727.Peer-Reviewed Original ResearchRenal replacement therapy requirementAlcohol-associated hepatitisMaddrey's discriminant functionShort-term mortalityFurther prospective studiesMELD-NaTherapy requirementsProspective studyEnd-stage liver diseaseHigh short-term mortalityGlobal cohortRetrospective cohort studyCompeting-risk analysisTime-dependent AUCMELD-sodiumLiver transplantationMalnourished patientsCohort studyEstablishment of treatmentLiver diseaseABIC scoreLargest global cohortMAIN OUTCOMEMortality predictionDeLong method
2021
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
Morales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes J, Cruz-Lemini M, Thursz M, Atkinson S, Sarin S, Kim W, Chavez-Araujo R, la Tijera M, Singal A, Shah V, Kamath P, Duarte-Rojo A, Charles E, Vargas V, Jager M, Rautou P, Rincon D, Zamarripa F, Restrepo-Gutiérrez J, Torre A, Lucey M, Arab J, Mathurin P, Louvet A, García-Tsao G, González J, Verna E, Brown R, Argemi J, Fernández-Carrillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study. The American Journal Of Gastroenterology 2021, 117: 301-310. PMID: 34962498, PMCID: PMC8999152, DOI: 10.14309/ajg.0000000000001596.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisMaddrey's discriminant functionShort-term mortalityMELD scoreMELD-sodiumEnd-stage liver disease (MELD) scoreGlasgow alcoholic hepatitis scoreMaddrey Discriminant Function scoreAlcohol‐Associated HepatitisMedian MELD scoreLiver Disease scoreInternational normalized ratioCharacteristic curveMDF scoreCause mortalityPrimary outcomeTertiary centerLaboratory variablesCreatinine scoreNormalized ratioFunction scoresDisease scoreMortality predictionMortalityOutcome predictionThe Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis
Musto JA, Eickhoff J, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Mathurin P, Garcia‐Tsao G, Schnabl B, Bataller R, Lucey MR. The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol‐Associated Hepatitis. Liver Transplantation 2021, 27: 1382-1391. PMID: 34109723, PMCID: PMC11075741, DOI: 10.1002/lt.26203.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisAUDIT-C scoresMELD-NaAUDIT-10Recent alcohol consumptionAlcohol consumptionLiver injuryLiver diseaseSurvival statusAUDIT-ConsumptionEnd-stage liver diseaseAUDIT scoresAlcohol‐Associated HepatitisProspective international databaseMELD-Na scoreAlcohol Use Disorders Identification TestShort-term mortalityShort-term outcomesPrior yearDisorders Identification TestSeverity of drinkingPresenting featuresPrimary outcomeClinical outcomesClinical severity